New antileishmanial and antitrypanosomal drugs
Description
The aim is to develop a natural product derived LEAD compound with unrivalled potency against a parasitic disease into a clinical drug candidate, through preclinical development. This includes the establishment of a detailed structure-activity relationship (SAR), medicinal chemistry and organic synthesis, ADME-Tox optimization, formulation, and in vivo studies.
Key Data
Projectlead
Project team
Dr. Stefano Agnello, Dr. Michael Brand, Flavio Gall, Dr. Silvia Gazzola, Luka Raguz
Project partners
BACOBA AG
Project status
completed, 09/2016 - 01/2019
Funding partner
KTI-Projekt / Projekt Nr. 19208.1 PFLS-LS
Project budget
2'043'672 CHF
Publications
-
Dissecting structural requirements of leucinostatin A derivatives for antiprotozoal activity and mammalian toxicity
2025 Rimle, Lukas; Pliatsika, Dimanthi; Arnold, Noëlle; Kurth, Sandra; Kaiser, Marcel; Mäser, Pascal; Kemmler, Michael; Adams, Michael; Riedl, Rainer; von Ballmoos, Christoph
-
Antiprotozoische Struktur‐Aktivitäts‐Beziehungen von synthetischen Leucinostatin‐Derivaten und Aufklärung ihres Wirkprinzips
2021 Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer
-
Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action
2021 Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer
-
Antiprotozoal compounds
2018
Einsiedlerstrasse 31
8820 Wädenswil